Expertise in
9
conditions

Dr. Jeffrey E. Rubnitz

Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
Offers Telehealth
Expertise in
9
conditions
262 Danny Thomas Pl, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Rubnitz is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Rubnitz is highly rated in 9 conditions, according to our data. His top areas of expertise are Childhood Acute Myeloid Leukemia, Leukemia, Acute Megakaryoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 175 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

262 Danny Thomas Pl, Memphis, TN 38105

Additional Areas of Focus

Dr. Rubnitz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) With an Isocitrate Dehydrogenase-2 (IDH2) Mutation
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) With an Isocitrate Dehydrogenase-2 (IDH2) Mutation
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Procedure, Drug
Study Drugs: Enasidenib, Enasidenib Mesylate
Study Phase: Phase 2
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Radiation, Other
Study Drugs: Bendamustine, Etoposide, Doxorubicin, Bleomycin, Vincristine, Vinblastine, Prednisone, Filgrastim, Brentuximab, Cyclophosphamide, Dacarbazine
Study Phase: Phase 2
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
A Phase I and Expansion Cohort Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug, Biological
Study Drugs: Venetoclax, Selinexor, Cytarabine, Fludarabine, Filgrastim, Methotrexate, Hydrocortisone
Study Phase: Phase 1
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma
Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Vinblastine, Mechlorethamine, Vincristine, Bleomycin, Etoposide, Prednisone
Study Phase: Phase 2
Adcetris (Brentuximab Vedotin), Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)
Adcetris (Brentuximab Vedotin), Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Brentuximab, Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Dacarbazine, Filgrastim
Study Phase: Phase 2
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug, Combination product, Biological
Study Drugs: Methotrexate, Hydrocortisone, Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, Idarubicin, Fludarabine, Mitoxantrone, Erwinia Asparaginase, Sorafenib, Granulocyte Colony-Stimulating Factor, Dexrazoxane
Study Phase: Phase 2
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Flotetuzumab
Study Phase: Phase 1
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cytarabine, Filgrastim, Fludarabine, Liposomal Daunorubicin, Liposomal Cytarabine
Study Phase: Phase 1/Phase 2
A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: February 14, 2023
Intervention Type: Drug
Study Drugs: Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
Study Phase: Phase 1
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug, Device
Study Phase: Phase 3
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: May 22, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: March 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Microtransplantation in Patients With Refractory or Relapsed Hematologic Malignancies
A Phase II Study of Microtransplantation in Patients With Refractory or Relapsed Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 01, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 16 Less Clinical Trials

175 Total Publications

Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Journal: Leukemia
Published: March 19, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Marcin W. Wlodarski
Pediatric Hematology Oncology
Expertise in
14
conditions
Dr. Marcin W. Wlodarski
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
888-226-4343
Languages Spoken:
English
See accepted insurances

Marcin Wlodarski is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Wlodarski is highly rated in 14 conditions, according to our data. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Dyskeratosis Congenita, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. Amar J. Gajjar
Pediatric Hematology Oncology
Expertise in
13
conditions
Dr. Amar J. Gajjar
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-3006
Languages Spoken:
English
See accepted insurances

Amar Gajjar is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Gajjar is highly rated in 13 conditions, according to our data. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

Expertise in
8
conditions
Dr. Deepa G. Manwani
Pediatric Hematology Oncology
Expertise in
8
conditions
Dr. Deepa G. Manwani
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-3300
Languages Spoken:
English
See accepted insurances

Deepa Manwani is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Manwani is highly rated in 8 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rubnitz's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile